ENDRA Life Sciences Files 8-K on Corporate Matters
Ticker: NDRA · Form: 8-K · Filed: Oct 29, 2024 · CIK: 1681682
| Field | Detail |
|---|---|
| Company | Endra Life Sciences INC. (NDRA) |
| Form Type | 8-K |
| Filed Date | Oct 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, disclosure
TL;DR
ENDRA filed an 8-K on Oct 28th covering votes and other key company events.
AI Summary
ENDRA Life Sciences Inc. filed an 8-K on October 29, 2024, reporting on matters submitted to a vote of security holders and other events that occurred on October 28, 2024. The filing details the company's corporate actions and significant events as of that date.
Why It Matters
This filing provides crucial updates on ENDRA Life Sciences' corporate governance and significant events, which can impact investor decisions and the company's strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of corporate events and does not appear to contain immediate financial risks.
Key Players & Entities
- ENDRA Life Sciences Inc. (company) — Registrant
- October 28, 2024 (date) — Date of earliest event reported
- October 29, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Ann Arbor, MI (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What other events are being reported in this 8-K?
The filing states that 'Other Events' are being reported, but the specific nature of these events is not detailed in the provided text.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on October 28, 2024.
What is the exact name of the registrant?
The exact name of the registrant is ENDRA Life Sciences Inc.
Where are ENDRA Life Sciences Inc.'s principal executive offices located?
ENDRA Life Sciences Inc.'s principal executive offices are located at 3600 Green Court, Suite 350, Ann Arbor, MI 48105.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2024-10-29 16:05:20
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share NDRA The Nasdaq Stock Mar
Filing Documents
- endra_8k.htm (8-K) — 24KB
- 0001654954-24-013446.txt ( ) — 144KB
- endra-20241028.xsd (EX-101.SCH) — 6KB
- endra-20241028_lab.xml (EX-101.LAB) — 14KB
- endra-20241028_cal.xml (EX-101.CAL) — 1KB
- endra-20241028_pre.xml (EX-101.PRE) — 9KB
- endra-20241028_def.xml (EX-101.DEF) — 2KB
- endra_8k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders ENDRA Life Sciences (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") on October 28, 2024. The certified results of the matter voted upon at the Special Meeting, which is more fully described in the definitive proxy statement for the Special Meeting as filed with the Securities and Exchange Commission on September 16, 2024, are as follows: Proposal 1 – The Company's stockholders approved amendments to the Company's Fourth Amended and Restated Certificate of Incorporation effecting reverse stock splits of its common stock at ratios between 1-for-4 and 1-for-35, inclusive, one of which reverse stock split ratios will be chosen, at the discretion of our Board of Directors on or prior to the one-year anniversary of the date of the Special Meeting, and the remainder of which reverse stock split ratios will be abandoned (the "Reverse Stock Split"): For Against Abstain 4,241,540 2,792,189 18,228
01 Other Events
Item 8.01 Other Events. Following the Special Meeting, the Board of Directors approved a ratio of 1-for-35 for the Reverse Stock Split. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENDRA Life Sciences Inc. October 29, 2024 By: /s/ Richard Jacroux Name: Richard Jacroux Title: Chief Financial Officer 3